Clinical trial
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic…
NCT00102687 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00102687 |
|---|---|
| Title | Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes |
| Official title | A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | azacitidine |
| Enrollment | 151 |
| Start date | Jan 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 1, 2005 |
| Last update posted | Nov 22, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: